Suppr超能文献

胶质母细胞瘤中非编码 RNA 的多变世界。

The protean world of non-coding RNAs in glioblastoma.

机构信息

Cellular Pathway Imaging Laboratory (CPIL), Molecular Imaging Program at Stanford, Stanford University School of Medicine, 3155 Porter Drive, Palo Alto, CA, 94305, USA.

Laboratory of Experimental and Molecular Neuroimaging (LEMNI), Molecular Imaging Program at Stanford, Stanford University School of Medicine, 300 Pasteur Drive, Grant S-031, Stanford, CA, 94305-5105, USA.

出版信息

J Mol Med (Berl). 2019 Jul;97(7):909-925. doi: 10.1007/s00109-019-01798-6. Epub 2019 May 25.

Abstract

Non-coding ribonucleic acids (ncRNAs) are a diverse group of RNA molecules that are mostly not translated into proteins following transcription. We review the role of ncRNAs in the pathobiology of glioblastoma (GBM), and their potential applications for GBM therapy. Significant advances in our understanding of the protean manifestations of ncRNAs have been made, allowing us to better decipher the molecular complexity of GBM. A large number of regulatory ncRNAs appear to have a greater influence on the molecular pathology of GBM than thought previously. Importantly, also, a range of therapeutic approaches are emerging whereby ncRNA-based systems may be used to molecularly target GBM. The most successful of these is RNA interference, and some of these strategies are being evaluated in ongoing clinical trials. However, a number of limitations exist in the clinical translation of ncRNA-based therapeutic systems, such as delivery mechanisms and cytotoxicity; concerted research endeavors are currently underway in an attempt to overcome these. Ongoing and future studies will determine the potential practical role for ncRNA-based therapeutic systems in the clinical management of GBM. These applications may be especially promising, given that current treatment options are limited and prognosis remains poor for this challenging malignancy.

摘要

非编码核糖核酸(ncRNAs)是一组多样化的 RNA 分子,它们在转录后大多不被翻译成蛋白质。我们回顾了 ncRNAs 在胶质母细胞瘤(GBM)发病机制中的作用,以及它们在 GBM 治疗中的潜在应用。我们对 ncRNAs 多变表现的理解取得了重大进展,使我们能够更好地解读 GBM 的分子复杂性。大量调节性 ncRNAs 似乎对 GBM 的分子病理学有比以前更大的影响。重要的是,也出现了一系列治疗方法,其中可能使用基于 ncRNA 的系统对 GBM 进行分子靶向治疗。其中最成功的是 RNA 干扰,其中一些策略正在进行中的临床试验中进行评估。然而,基于 ncRNA 的治疗系统的临床转化存在许多限制,例如递药机制和细胞毒性;目前正在进行协同的研究努力,试图克服这些限制。正在进行和未来的研究将确定基于 ncRNA 的治疗系统在 GBM 临床管理中的潜在实际作用。鉴于目前的治疗选择有限,且这种具有挑战性的恶性肿瘤的预后仍然较差,这些应用可能特别有前途。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验